Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SVX-24
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : RA Capital Management
Deal Size : $110.0 million
Deal Type : Series D Financing
Details : SutroVax has generated preclinical proof of concept versus the standard of care vaccines and intends to advance SVX-XP into the clinic as a future successor to SVX-24.
Product Name : SVX-24
Product Type : Vaccine
Upfront Cash : Undisclosed
March 26, 2020
Lead Product(s) : SVX-24
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : RA Capital Management
Deal Size : $110.0 million
Deal Type : Series D Financing